15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Oncolytics Biotech Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $5.00 to $5.00, so the covering firms are broadly aligned. The average target of $5.00 sits 495% above the current $0.84. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.34 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Oncolytics Biotech Inc.
As of Sep, 1 of 1 firms rate ONCY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ONCY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.08 · 3 analysts
Next period, 3 analysts expect Oncolytics Biotech Inc to earn $-0.08 a share (range $-0.08 – $-0.08), versus — a year earlier. Full-year consensus is $-0.38, growing to $-0.34 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Oncolytics Biotech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ONCY.
#1
DM
Douglas Miehm
RBC Capital · Rank #190
Buy
$3.50+316.7% to target
Overall win rate
43%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #230
Buy
$5.00+495.2% to target
Overall win rate
36%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #428
Buy
$3.00+257.1% to target
Overall win rate
32%
+ Follow
#4
DL
Douglas Loe
Leede Financial
Buy
$4.00+376.2% to target
Coverage
—
+ Follow
#5
CM
Chad Messer
Lake Street
Buy
$7.00+733.3% to target
Coverage
—
+ Follow
ONCY stock forecast FAQ
What is ONCY's average 12-month price target?+
The 1 analysts with a live target average $5.00 for Oncolytics Biotech Inc over the next 12 months, ranging from a $5.00 high to a $5.00 low.
Is ONCY stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover ONCY?+
1 analysts have an active rating on Oncolytics Biotech Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering ONCY?+
Among analysts who currently cover ONCY, Douglas Miehm of RBC Capital has the strongest overall Quantellect track record (Rank #190). Their current call is Buy with a $3.50 target.
What is Oncolytics Biotech Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.08) across 3 analysts. Full-year EPS is projected at $-0.38, rising to $-0.34 the following year.
How much revenue is Oncolytics Biotech Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ONCY lately?+
As of Sep, 1 of 1 firms rate ONCY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ONCY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
